Skip to main content
Stefan K. Barta on Muck Rack

Stefan K. Barta

As seen in: Color Research & Application, Nature, Wiley Online Library, MDPI, HemOnc Today, Chinese Clinical Oncology, Targeted Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stefan K.

Contact Stefan K., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma

|
By John Sharp, Subodh Bhatta, Jennifer Huang, Colin Thomas Verified, Omar Elghawy, Lindsey A. Fitzgerald, Daniel Reef, Timothy Voorhees, Supriya Gupta, Natalie Grover Verified, Stefan K. Barta, Mazyar Shadman, Narendranath Epperla, Andinet Teferra
| Nature Verified
Dear Editor, Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma, with approximately 14,000 new diagnoses annually in the United States. Although FL has historically been considered incurable, front-line therapy can induce durable remissions. Nevertheless, up to 50% of patients require multiple lines of treatment [1].
Open in Who Shared Issue with article?

Naïve CD4 + T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

|
By Michael Schneider, Luca Paruzzo, Federico Stella, Julia Han Noll, Matthew Ho, Victor Babatunde, Bianca Ho, Pooja Devi, Elise Chong, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Jordan Carter, Michael Cook, Nasheed M. Hossain, Colin Thomas Verified, Vitor De Souza, Mohannad H Alkhatib, Ziyu Li, Melody Tan, Peter Michener, Puneeth Guruprasad, Alberto Carturan, Patrizia Porazzi, Joseph A Fraietta, Stephen J. Schuster, Ivan Maillard, Marco Ruella, Daniel J. Landsburg, Vrutti Patel, Antonio Imparato
| Nature Verified
Open in Who Shared Issue with article?

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

|
By Yucai Wang, Melissa Larson, Steven Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar Verified, Ashlee Joseph, Taylor Brooks, Brian Hill, David Bond, Kami J. Maddocks, Alexey B. Danilov, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Natalie Grover Verified, Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey Harris, Javier Muñoz, Philip Young, Craig Portell, Patrick M Reagan, Christine Ryan, Reid W. Merryman, Arash Velayati, Drew Gerber, Preetesh Jain, Michael Wang, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony Stack, Marcus Messmer, Mayur Narkhede, Amitkumar Mehta, Nilanjan Ghosh, Rahul S Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob L. Anna, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon Cohen, Peter Martin, Christine Argao, Nazneen B. Khan, I. Brian Greenwell, Sabarish R. Ayyappan, Tamara K. Moyo, Alexander V. Stanisic
| Nature Verified
Abstract Addition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020.
Open in Who Shared Issue with article?
See all 17 licensed articles (18 Total)